Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KMDA by emailGet an email when KMDA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KMDA, unsubscribe in one click. Privacy
📣 What KMDA Says Is Next
In 2026 · “We are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively, representing 12% and 23% growth when comparing 2026 guidance mid-points to 2025 results.” “In 2026, our focus remains on the expansion of our entire commercial product portfolio, including our six FDA-approved specialty plasma-derived products.”
Company press release, May 13, 2026 · SEC filing
IN 2026 · “KAMADA ANNOUNCES DISCONTINUATION OF ITS PHASE 3 INHALED AAT CLINICAL TRIAL; REITERATES 2025 FULL-YEAR GUIDANCE AND PROJECTS DOUBLE-DIGIT GROWTH IN REVENUES AND PROFITABILITY IN 2026 Exhibit 99.1 Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026”
Company press release, Dec 8, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KMDA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KMDA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.